Safety and Tolerability of Zongertinib in HER2-Positive NSCLC

Joshua K. Sabari, MD, highlights the safety and tolerability of the HER2-selective TKI zongertinib in patients with HER2 mutation–positive non–small cell lung cancer, as observed in the Beamion LUNG‑1 trial. He specifically covers the incidence and management of diarrhea and rash. Sabari also compares the safety and tolerability of zongertinib vs other agents used in this setting.